| Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program JG Katzman, MY Takeda, N Greenberg, MM Balasch, A Alchbli, ... JAMA network open 3 (2), e200117-e200117, 2020 | 47 | 2020 |
| Glycolic acid chemical peeling improves inflammatory acne eruptions through its inhibitory and bactericidal effects on Propionibacterium acnes Y Takenaka, N Hayashi, M Takeda, S Ashikaga, M Kawashima The Journal of Dermatology 39 (4), 350-354, 2012 | 33 | 2012 |
| Co-prescription of naloxone as a universal precautions model for patients on chronic opioid therapy—observational study MY Takeda, JG Katzman, E Dole, MH Bennett, A Alchbli, D Duhigg, ... Substance abuse 37 (4), 591-596, 2016 | 25 | 2016 |
| An innovative model for naloxone use within an OTP setting: a prospective cohort study JG Katzman, MY Takeda, SR Bhatt, MM Balasch, N Greenberg, H Yonas Journal of addiction medicine 12 (2), 113-118, 2018 | 24 | 2018 |
| Opioid overdose response training in pharmacy education: an analysis of students’ perception of naloxone use for opioid overdose prevention A Bachyrycz, MY Takeda, K Wittstrom, B Bleske Currents in Pharmacy Teaching and Learning 11 (2), 166-171, 2019 | 21 | 2019 |
| Characteristics of patients with opioid use disorder associated with performing overdose reversals in the community: an opioid treatment program analysis JG Katzman, NH Greenberg, MY Takeda, MM Balasch Journal of Addiction Medicine 13 (2), 131-138, 2019 | 18 | 2019 |
| Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico JG Salvador, AL Sussman, MY Takeda, WG Katzman, M Moya Balasch, ... Harm Reduction Journal 17, 1-8, 2020 | 14 | 2020 |
| Energy Drink-Induced Breakthrough Seizure in a Patient on Valproic Acid—Considering Herbal Safety in Epilepsy M Yamada-Takeda, A Patel, G Fenton Journal of Pharmacy Practice 32 (5), 485-487, 2019 | 8 | 2019 |
| “You've got to care to carry this stuff” Community implications from take-home naloxone use: A qualitative study M Kano, JG Salvador, W Katzman, AL Sussman, MY Takeda Journal of Substance Abuse Treatment 115, 108030, 2020 | 2 | 2020 |
| Debriefing to Improve Student ability to assess and plan for the care of persons with disability MY Takeda, MJ Smith, CJ Cone Simulation in Healthcare 12 (6), 356-363, 2017 | 2 | 2017 |
| Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy MH Roberts, MY Takeda, S Kindilien, YK Barqawi, ME Borrego Expert review of pharmacoeconomics & outcomes research 18 (5), 487-503, 2018 | 1 | 2018 |
| Technique for peeling of epiretinal membranes M Takeda JAPANESE JOURNAL OF CLINICAL OPHTHALMOLOGY 55 (1), 72-84, 2001 | 1 | 2001 |
| Development and validation of an indicator to identify prescriptions as non-opioid pharmacological therapies used for pain management through the use of electronic health … R Lane, LE Tomedi, M Takeda, N Hood, JG Katzman Pain Medicine 25 (6), 416-418, 2024 | | 2024 |
| Development of Clinical Pharmacy Rotation in Japan M Takeda, T Hunter, J Anderson, B Bleske, D Godwin | | 2023 |
| Standardized Patient Assessment of Communications in Pharmacy and Medical Students J Nawarskas, M Takeda, P Marshik, A Herman, M Vilay, K Salazar, ... | | 2019 |
| Development of New-IGISOL at CYRIC T Sonoda, M Fujita, A Yamazaki, T Ohshima, M Takeda, E Tanaka, ... CYRIC annual report 2000, 45-49, 2000 | | 2000 |
